- Chemical and generic drugs dominate, with few innovative drugs — competition plays out in channels, marketing, and field promotion
- High Share of Sales Expense
- “Consistency evaluation” policy is pushing product innovation
- A fast-changing environment and heavy policy impact mean product demand shifts often — companies need to respond with agility
- National Insurance Cost Controls Put Pressure on Drug Pricing
- Expense-driven performance and gray-area incentives touch both individuals and the system, making clear, transparent spend hard to achieve
- Without upfront oversight, expense control tends to happen only after the fact
- The “two-invoice” system and pass-through audits mean strict oversight, heavy compliance pressure, and high disclosure requirements
- High travel spend, tedious reimbursement, slow payment, low satisfaction all around
- Heavy compliance requirements, hard-to-manage documents, employees easily pick the wrong account, and finance faces a heavy review load
- One task, many disconnected processes
- Management approves the same thing multiple times, without a clear view of the full picture or real control over product profit















